Itk inhibitors: A patent review

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 4, 2010, Pages 459-469

  Lo, Ho Yin ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

HIV; Inflammation; Itk; T cell; Tyrosine kinase

Indexed keywords

AMINOPYRIDINE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; BMS 488516; BMS 509744; INDOLE DERIVATIVE; INTERLEUKIN 2 INDUCIBLE T CELL KINASE INHIBITOR; MICRORNA; PEPTIDE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; POLYPEPTIDE; PROTEIN TYROSINE KINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINE DERIVATIVE; R9 QQP PEPTIDE; SMALL INTERFERING RNA; THIAZOLE DERIVATIVE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG QUALITY; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PNEUMONIA; REVIEW; VALIDITY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; INFLAMMATION; INTERLEUKINS; PATENTS AS TOPIC; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 77949878560     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543771003674409     Document Type: Review

References (51)

1. Smith CIE, Islam TC, Mattsson PT, et al. The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species. Bioessays 2001;23:436-446
2. Forssell J, Sideras P, Eriksson C, et al. Interleukin-2-inducible T cell kinase regulates mast cell degranulation and acute allergic responses. Am J Respir Cell Mol Biol 2005;32:511-520
3. Schaeffer EM, Yap GS, Lewis CM, et al. Mutation of Tec family kinases alters T helper cell differentiation. Nat Immune 2001;2:1183-1188
4. Schaeffer EM, Debnath J, Yap G, et al. Requirement for Tec kinases Rlk and Itk in T cell receptor signaling and immunity. Science 1999;284:638-641
5. Fowell DJ, Shinkai K, Liao XC, et al. Impaired NFATc Translocation and Failure of Th2 Development in Itk-Deficient CD4+ T cells. Immunity 1999;11:399-409
6. Qian D, Weiss A. T cell antigen receptor signal transduction. Curr Opin Cell Biol 1997;9:205-212
7. Kanner SB, Perez-Villar JJ. Altering T-cell activation by targeting the multidomain tyrosine kinase Itk. Trends in Immunology 2003;24:249-253
8. Samelson LE. Signal transduction mediated by the T cell antigen seceptor: the role of adapter proteins. Annu Rev Immunol 2002;20:371-394
9. Mueller C, August A. Attenuation of immunological symptoms of allergic asthma in mice lacking the tyrosine kinase ITK. J Immunol 2003;170:5056-5063
10. Wong WS. Inhibitors of the tyrosine kinase signaling cascade for asthma. Curr Opin Pharmacol 2005;5:264-271
11. Lin T, McIntyre KW, Das J, et al. Selective Itk inhibitors block T-cell activation and murine lung inflammation. Biochemistry 2004;43:11056-11062
12. Matsumoto Y, Oshida T, Obayashi I, et al. Identification of highly expressed genes in peripheral blood T cells from patients with atopic dermatitis. Int Arch Allergy Immunol 2002;129:327-340
13. Graves PE, Siroux V, Guerra S, et al. Association of atopy and eczema with polymorphisms in T-cell immunoglobulin domain and mucin domain- IL-2-inducible T-cell kinase gene cluster in chromosome 5q33. J Allergy Clin Immunol 2005;116:650-656
14. Readlinger JA, Schiralli GM, Thomas JJ, et al. Selective targeting of ITK blocks multiple steps of HIV replication. Proc Natl Acad Sci USA 2008;105:6684-6689
15. Yu L, Mohanram V, Simonson OE, et al. Proteasome inhibitors block HIV-1 replication by affecting both cellular and viral targets. Biochem Biophys Res Comm 2009;385:100-105
16. Brown K, Long JM, Vial SCM, et al. Crystal structures of interleukin-2 tyrosine kinase and their implications for the design of selective inhibitors. J Biol Chem 2004;279:18727-18732
17. Vertex Pharmaceuticals, Inc. Crystal structure of interleukin-2 tyrosine kinase (ITK) and binding pockets thereof. WO2005056785
18. Boehringer Ingelheim Pharmaceuticals, Inc. Crystal structure of the interleukin-2-inducible cell kinase (ITK) kinase domain. WO2005066335
19. Bristol-Myers Squibb Pharmaceuticals Research Institute. Thiazolyl inhibitors of Tec family tyrosine kinases. WO2002050071
20. Das J, Liu C, Moquin RV, et al. Discovery and SAR of 2-amino-5- [thiomethyl)aryl]thiazoles as potent and selective Itk inhibitors. Bioorg Med Chem Lett 2006;16:2411-2415
21. Das J, Furch JA, Liu C, et al. Discovery and SAR of 2-amino-5-(thioaryl) thiazoles as potent and selective Itk inhibitors. Bioorg Med Chem Lett 2006;16:3706-3712
22. Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds. WO2004014905
23. Boehringer Ingelheim Pharmaceuticals, Inc. 1H-benzimidazol-2-yl-benzamide derivatives and related compounds as ITK inhibitors (interleukin-2-inducible T cell kinase) for the treatment of inflammation, immunological and allergic disorders. WO2005070420
24. Boehringer Ingelheim Pharmaceuticals, Inc. Thiophene-2-carboxylic acid-(1Hbenzimidazol- 2 yl)-amide derivatives and related compounds as inhibitors of the Tec kinase ITK (interleukin-2-inducible T cell kinase) for the treatment of inflammation, immunological and allergic disorders. WO2005079791
25. Snow RJ, Abeywardane A, Campbell S, et al. Hit-to-Lead studies on benzimidazole inhibitors of ITK: discovery of a novel class of kinase inhibitors. Bioorg Med Chem Lett 2007;17:3660-3665
26. Moriarty KJ, Winters M, Qiao L, et al. Itk kinase inhibitors: initial efforts to improve the metabolical stability and the cell activity of the benzimidazole lead. Bioorg Med Chem Lett 2008;18:5537-5540
27. Winters MP, Robinson DJ, Khine HH, et al. 5-Aminomethyl-1H-benzimidazoles as orally active inhibitors of inducible T-cell kinase (Itk). Bioorg Med Chem Lett 2008;18:5541-5544
28. Moriarty KJ, Takahashi H, Pullen SS, et al. Discovery, SAR and X-ray structure of 1H-benzimidazole-5-carboxylic acid cyclohexyl-methyl-amides as inhibitors of inducible T-cell kinase (Itk). Bioorg Med Chem Lett 2008;18:5545-5549
29. Lo HY, Bentzien J, Fleck RW, et al. 2-Aminobenzimidazoles as potent ITK antagonists: trans-stilbene-like moieties targeting the kinase specificity pocket. Bioorg Med Chem Lett 2008;18:6218-6221
30. Lo HY, Bentzien J, White A, et al. 2-Aminobenzimidazoles as potent ITK antagonists: de novo design of a pyrrole system targeting additional hydrogen bonding interaction. Tetrahedron Lett 2008;49:7337-7340
31. Cook BN, Bentzien J, White A, et al. Discovery of potent inhibitors of interleukin-2 inducible T-cell kinase (ITK) through structure-based drug design. Bioorg Med Chem Lett 2009;19:773-777
32. Riether D, Zindell R, Kowalski JA, et al. 5-Aminomethylbenzimidazoles as potent ITK antagonists. Bioorg Med Chem Lett 2009;19:1588-1591
33. Boehringer Ingelheim Pharmaceuticals, Inc. Tec kinase inhibitors. WO2007076228
34. Boehringer Ingelheim Pharmaceuticals, Inc. Tec kinase inhibitors. WO2007058832
35. Astrazeneca AB. Substituted pyrrolopyridines. WO2004016610, US20050266331
36. Astrazeneca AB. Use of and some novel imidazopyridine. WO2004016611, US20050261333
37. Astrazeneca AB. Novel use of benzothiazole derivatives. WO2004016600, US20060106015
38. Astrazeneca AB. Pyrazolo (4, 3c) cinnoline compounds as inhibitors of ITK kinase activity. WO2004016615
39. Sanofi-aventis. Thienopyrazoles. WO2005026175, US20070254937
40. Vertex Pharmaceuticals, Inc. Pyrid-2-ones useful as inhibitors of TEC family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases. WO2006065946, US20060183911
41. Vertex Pharmaceuticals, Inc. 3,5-disubstituted pyrid-2-ones useful as inhibitors of Tec kinase family of non-receptor tyrosine kinases. WO2007027594, CA2620269
42. Vertex Pharmaceuticals, Inc. 3,5-disubstituted pyrid-2-ones useful as inhibitors of Tec kinase family of non-receptor tyrosine kinases. WO2007027729, CA2620352
43. Bayer Schering Pharma AG. Sulfoximine-substituted pyrimidines, their preparation and use as drugs. WO2007017455, US20070232632
44. Cellzome. Aminopyridine derivates as kinase inhibitors. WO2008025820, EP1900727
45. Cellzome. Diazolodiazine derivatives as kinase inhibitors. WO2008025822, EP1900739
46. Cellzome. Triazole derivatives as kinase inhibitors. WO2008025821, EP1894931
47. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-1657
48. San Diego State University Research Foundation. Compositions and methods for inhibiting inducible T cell kinase (ITK) and treating asthma and bronchial inflammations. WO2008144351
49. Jansen PM, Jan Danser AH, Imholz BP, et al. Aldosterone-receptor antagonism in hypertension. J Hypertens 2009;6:80-691
50. Brugts JJ, Ferrari R, Simoons ML. Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease. Expert Rev Cardiovasc Ther 2009;7:345-360
51. Huck K, Feyen O, Niehues T, et al. Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. J Clin Invest 2009;119:1350-1358